FDA
-
-
-
-
-
-
-
Cocrystal Pharma begins dosing first subjects in norovirus drug trial
-
-
-
-
-
-
-
Cocrystal Pharma gets FDA clearance for norovirus drug study
-
-
-
-
-
-
-
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
-
-
-
-
-
-
-
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
-
-
-
-
-
-
-
Cocrystal Pharma (COCP) Reports FY22 Results, Provides Updates on its Antiviral Drug Development Programs
-
-
-
-
-
-
-
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
-
-
-
-
-
-
-
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
-
323,958 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

